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ABSTRACT
Background: Hepatitis C virus (HCV) and hepatitis B virus (HBV) infection are especially prob-
lematic in patients with end-stage renal disease who are undergoing hemodialysis (HD).
Objectives: To determine the prevalence of HCV and HBV infection in HD population in Gui-
lan, north of Iran.
Patients and Methods: In a cross-sectional study, from May to September 2009, in 11 different 
hemodialysis units in Guilan province, North of Iran, clinical data such as age, gender, dura-
tion of dialysis, HBsAg and anti-HCV antibody of 514 HD patients were recorded. Patients with 
positive antibodies against HCV were tested for HCV RNA.
Results: From 514 patients, 286 (55.64%) were male. 61 (11.9%) patients were anti-HCV-positive 
and 31 (50.8%) were HCV PCR-positive. There was significant relationship between HCV Ab-
positivity with gender and HD duration (p < 0.05). There was significant difference between 
the mean HD duration in anti-HCV-positive and anti-HCV-negative patients (p < 0.05). Also, 
significant relationship was found between HCV RNA-positivity with gender and HD dura-
tion (p < 0.05). Seven (1.4%) patients were positive for HBsAg. Two (0.38 %) were found positive 
for both HBsAg and anti-HCV antibody.
Conclusions: There is low a prevalence of HCV and HBV in HD patients in our region. The rate 
can be decreased by HBV vaccination of end-stage renal disease patients before setting chron-
ic HD, antiviral treatment and isolation of infected individuals.
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Background
Hepatitis C virus (HCV) infection is especially problemat-
ic in patients with end-stage renal disease (ESRD) who are 
undergoing hemodialysis (HD) (1). The prevalence of HCV 
infection is higher among HD patients than in the general 
population, and several routes of transmission are thought 
to originate from the HD unit (1, 2). There is wide variation in 
the prevalence of HCV infection among different HD units 
and countries as shown by Dialysis Outcomes and Practice 
Patterns Study (DOPPS). The mean prevalence of HCV in dif-
ferent  HD  facilities  is  13.5%  and  varied  among  countries 
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from 2.6% to 22.9% (3). The main reasons for such a high in-
cidence of infections are a high prevalence of HCV infection 
in the general population, lack of standard infection precau-
tions and effective vaccination, inadequate disinfection pro-
cedures of dialysis machines and other medical equipment, 
as well as spread of infection from patient to patient, espe-
cially in dialysis centers with a high percentage of infected 
patients. The diagnostic procedures used in the evaluation 
of HCV infection are detection of anti-HCV antibodies, iden-
tification of HCV RNA, counts of virus copies, and identifica-
tion of its genome (4, 5). HCV infection is associated with 
greater mortality (6-8). As a cause of death, hepatocellular 
carcinoma  and  liver  cirrhosis  are  significantly  more  fre-
quent among anti-HCV-positive than anti-HCV-negative di-
alysis patients (9). Risk factors for HCV infection in dialysis 
patients  include  number  of  blood  transfusions,  duration 
of HD, mode of dialysis, prevalence of HCV infection in the Hepat Mon. 2011;11(3):178-181
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dialysis unit, previous organ transplantation, intravenous 
drug use, male gender, older age, previous HBV infection 
and nosocomial transmission of HCV in HD units (10-13).
HBV infection is less prevalent than HCV in HD units. The 
rate of serum HBsAg seropositivity on maintenance HD in 
the developed world is currently low (< 10%) but outbreaks 
of acute HBV infection continue to occur in this setting. The 
prevalence of HBV infection within dialysis units in develop-
ing countries however is higher (2%–20%), according to sev-
eral reports (14). HBV infection is a major clinical problem, 
as it can lead to many serious consequences, including acute 
and chronic hepatitis, cirrhosis, hepatocellular carcinoma 
and hepatic failure (15, 16). Universal precaution measures 
should be strictly observed and the segregation of HBsAg-
positive patients on HD should be practiced. Early vaccina-
tion against HBV before the start of ESRD remains the best 
way to secure immunological protection against HBV infec-
tion in dialysis patients (17).
Objectives
In this study we aimed to determine evaluation of HCV and 
HBV infection in HD population in Guilan, North of Iran.
Patients and Methods
In  a  cross-sectional  study,  clinical  and  epidemiological 
data were obtained from May to September 2009 in 11 differ-
ent HD units in Guilan province, northern Iran A total of 514 
patients were recruited from different cities of Anzali (n = 
34), Astaneh (n = 36), Astara (n = 20), Fouman (n = 18), Lahijan 
(n = 56), Langaroud (n = 38), Rasht (n = 159), Roudbar (n = 
17), Roudsar (n = 57), Soumesara (n = 40), and Talesh (n = 39). 
Clinical data such as age, gender, duration of dialysis, HBsAg 
and  anti-HCV  antibody  status  were  recorded.  Serological 
testing for HBsAg and anti-HCV antibody were performed on 
the recruited HD patients using third generation enzyme-
linked immunosorbent assay (ELISA) kit. Consecutively, pa-
tients with positive antibodies against HCV were tested by 
seroconversion  and  real-time  polymerase  chain  reaction 
(PCR) for detecting HCV RNA to eliminate false-negative cas-
es. Based on the duration of HD, patients were divided into 
four groups of < 5, 5–10, 10–15, and > 15 years.
SPSS® ver 14 for Windows® was used to analyze data. Quan-
titative variables were expressed as mean ± SD. To evaluate 
risk factors associated with HCV infection, x² test was used. 
Student’s t test was used to compare between means of two 
continuous variables. A p value < 0.05 was considered statis-
tically significant.
Results
Of 514 patients studied, 228 (44.35%) were female and 286 
(55.64%) were male (Table 1). The mean age of participants 
was 54.8 (range: 16–66) years. In this study, 61 (11.9%) were an-
ti-HCV-positive and 31 (50.8%) were HCV PCR-positive. Among 
those with positive anti-HCV antibody, 26 aged between 50 
and  70  years.  There  was  significant  relationship  between 
HCV antibody positivity with gender and dialysis duration 
(p < 0.05). No correlation was found between age with HCV 
antibody positivity (Table 1). The mean ± SD dialysis dura-
tion  in  anti-HCV-positive  and  anti-HCV-negative  patients 
was 5.47 ± 4.62 and 3.10 ± 2.75 years, respectively (p < 0.05). 
Significant correlation was found between HCV RNA-posi-
tivity with gender and dialysis duration (p < 0.05). On the 
contrary, no significant correlation was found between age 
and HCV RNA-positivity (Table 1). The mean ± SD dialysis du-
ration in HCV RNA-positive and HCV RNA-negative patients 
was 6.15±5.08 and 4.72 ± 4.02 years, respectively (p > 0.05). 
In this study, seven (1.4%) patients were HBsAg positive, six 
(1.16%) HBsAg-positive patients were male, four (0.7%) aged 
50–70 years, and five (0.9%) had dialysis duration of < 5 years 
(Table 1). Two (0.38 %) patients were found positive for both 
HBsAg and anti-HCV antibody.
HCV Antibody HCV RNA HBsAg
Positive 
No (%)
Negative 
No (%)
Total p-value Positive
No (%)
Negative
No (%)
Total p-value Positive
No (%)
Negative
No (%)
Total
Gender <0.05 <0.05
Male 41 (14.3) 245 (85.7) 286 41 (14.3) 245 (85.7) 286 6 (2.1) 280 (97.9) 286
Female 20 (8.8) 208 (91.2) 228 20 (8.8) 208 (91.2) 228 1 (0.4) 227 (99.6) 228
Age
(year)
NS NS
<30 7 (16) 39 (84) 46 7 (16) 39 (84) 46 0 (0) 46 (100) 46
30–50 21 (17.8) 97 (82.2) 118 21 (17.8) 97 (82.2) 118 2 (1.7) 116 (98.3) 118
50–70 26 (10.4) 224 (89.6) 250 26 (10.4) 224 (89.6) 250 4 (1.6) 246 (98.4) 250
>70 7 (7) 93 (93) 100 7 (7) 93 (93) 100 1 (1.1) 99 (99) 100
Dialysis Duration
(year)
<0.05 <0.05
< 5 38 (9) 382 (91) 420 38 (9) 382 (91) 420 5 (1.2) 415 (98.8) 420
5–10 15 (20) 61 (80) 76 15 (20) 61 (80) 76 2 (3) 74 (97) 76
10–15 5 (38) 8 (62) 13 5 (38) 8 (62) 13 0 (0.0) 13 (100) 13
> 15 3 (60) 2 (40) 5 3 (60) 2 (40) 5 0 (0.0) 5 (100) 5
Table 1. HCV antibody, HCV RNA and HBsAgdistribution according to gender, age group, dialysis duration in hemodialysis patientsHepat Mon. 2011;11(3):178-181
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Discussion
HCV infection remains highly prevalent both in developed 
(18) and less-developed countries (19). In spite of consider-
able decline in the incidence and prevalence of HCV infection 
among HD patients in many countries, this infection still 
remains a major problem among patients on maintenance 
HD (20, 21). The prevalence of HCV infection found in our 
HD patients (11.9%) was lower than that seen in other stud-
ies. Telaku, et al, studied 583 ESRD patients on maintenance 
HD from six HD centers in Kosova. They reported an anti-HCV 
antibody prevalence rate of 43% (14). In a descriptive study 
conducted by Alavian, et al, the prevalence of positive HCV 
antibodies decreased from 14.4% in 1999 to 4.5% in 2006 (22). 
Assarehzadegan, et al, studied 214 HD patients in West-south 
of Iran and found 34 patients positive for anti-HCV (7.9%, 95% 
CI:  4.32%–11.56%).  In  that  study,  although  anti-HCV  positiv-
ity in HD patients in Khuzestan province was smaller than 
those found in some other Iranian provinces and neighbor-
ing countries, the prevalence was still high (23). A retrospec-
tive study performed by Boulaajaj, et al, on 186 chronic HD 
patients, reported a high prevalence of HCV infection (76%) 
(24). Olut, et al, showed that seroprevalence of HCV infection 
was 19% among 437 HD patients (14-25). Silva, et al reported 
that anti-HCV seroprevalence among HD patients was 10.5% 
(26). Mansour-Ghanaei, et al, showed that 18.40% of 163 stud-
ied HD patients were found positive for anti-HCV antibody 
by ELISA (27). In a descriptive study conducted by Taziki, et 
al, they showed that the prevalence of HCV infection in HD 
patients has decreased significantly during the past decade 
in most HD units in the province of Mazandaran, northern 
Iran; in December 2001, the prevalence of antibody against 
HCV was 18%, whereas by December 2006, it was 12% (28). 
The overall prevalence of anti-HCV antibodies was 12.7% in 
report of Ocak, et al (29). Hussein, et al, studied 180 HD pa-
tients and identified 34 (18.9%) patients positive for anti-HCV 
antibody (30). In our study, prevalence of HCV RNA was 50.8 
% which was lower than other reports. In a study performed 
by Silva, et al, HCV-RNA was detected in 92 (73.6%) of 125 anti-
HCV-positive patients (26). Dattolo, et al, showed that HCV-
RNA was positive in 18 (75%) of 24 anti-HCV-positive subjects 
(31). Mansour-Ghanaei, et al, showed that 10.42% of 163 HD 
patients were positive for HCV RNA by PCR (27). Ocak, et al, 
reported a HCV RNA prevalence of 10.1% (29) The latter two 
prevalence rates which are lower than ours, were calculated 
based on all patients, whereas our rate was estimated based 
on anti-HCV-antibody-positive patients. In our study, signifi-
cant correlation was found between anti-HCV antibody with 
gender and duration of HD. Furthermore, significant corre-
lation was seen between HCV RNA seroprevalence and age 
and duration of HD.
Several studies were performed round the globe which fo-
cused on HCV seroprevalence in HD patients and its relation-
ship with risk factors. These studies had variable results. In 
a study by Assarehzadegan, et al, the duration of treatment 
with HD was significantly associated with HBV- and HCV-pos-
itivity (p < 0.001) (23). Sekkat, et al, reported a seroprevalence 
rate of HCV of 68.3%. HCV seropositivity was associated with 
longer duration of dialysis (p < 0.001) (32). Soto-Salgado, et 
al, using bivariate analysis revealed that in HD patients age 
was significantly (p = 0.05) associated with anti-HCV positiv-
ity (33). Salama, et al, I a multivariate analysis demonstrated 
that HCV status was linked to HD duration (34). El-Amin, et al, 
found that prevalence of HCV was 23.7%; HCV seropositivity 
was associated with longer duration of dialysis (p < 0.001) 
and age of over 30 (p = 0.008) (35). A high prevalence of HCV 
infection was observed in the study conducted by Iwasaki, 
et al; 23.9% and 26.8% of the 142 studied patients were posi-
tive for anti-HCV antibody and HCV RNA, respectively. These 
positive rates correlated with the duration of HD (36). Frei-
tas studied 163 patients in five dialysis units. The prevalence 
of anti-HCV was 11%. Length of HD was associated with HCV 
infection. HCV RNA was detected in 12 samples (37). Jabbari, 
et al, studied 93 HD patients in Golestan province of Iran 
and found that the mean duration of HD was higher in anti-
HCV-antibody positive cases (p < 0.05) (38). Ohsawa, et al, re-
ported that the prevalence of anti-HCV antibody was 12.5% in 
male HD patients and 8.5% in female HD patients (39). Preva-
lence of HCV infection in Dialysis Unit Gracanica was 46.5%. 
Men were more HCV-positive (59.3%) (16 of 27 patients). In 
anti-HCV-positive patients, 85% were positive for HCV RNA. 
Duration of dialysis therapy was longer in anti-HCV-positive 
patients (6.8 years) than in anti-HCV-negative patients (1.6 
years) (40). In our study, seroprevalence of HBsAg was 1.4% 
in HD patients which was lower than that reported in other 
studies from our country and other regions. That would be 
attributed to effective vaccination and isolation of infected 
patients. Telaku, et al, reported a HBsAg prevalence rate of 12% 
(14). Alavian, et al, reported that the seropositivity for HBsAg 
decreased from 3.8% in 1999 to 2.6% in 2006 (22). Assarehza-
degan, et al, reported that among 214 HD patients, 5.1% were 
positive for HBsAg (23). In a study conducted by Boulaajaj, et 
al, on 186 chronic HD patients, the prevalence of HBV infec-
tion was 2% (24). Mahdavizadeh, et al, found 64 (2.4%) HBsAg-
positive patients in 2630 HD patients of Tehran province, 
Iran (41). Al Hijazat, et al, showed that among 427 patients 
on HD, 5.9% became HBsAg-positive during the study period. 
Being on HD for longer than two years was more frequently 
noticed in the HBsAg-positive (88%) than in HBsAg-negative 
group (43%). Of these patients, 94% patients who remained 
HBsAg-negative and 4% of those who converted to HBsAg-
positive were reportedly vaccinated (17). There is low preva-
lence of HCV and HBV infection in HD population of our 
region and it can be decreased by HBV vaccination of ESRD 
patients before setting chronic HD, antiviral treatment and 
isolation of infected individuals.
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